首页> 外文期刊>Frontiers in Immunology >Expression of Siglec-E Alters the Proteome of Lipopolysaccharide (LPS)-Activated Macrophages but Does Not Affect LPS-Driven Cytokine Production or Toll-Like Receptor 4 Endocytosis
【24h】

Expression of Siglec-E Alters the Proteome of Lipopolysaccharide (LPS)-Activated Macrophages but Does Not Affect LPS-Driven Cytokine Production or Toll-Like Receptor 4 Endocytosis

机译:Siglec-e的表达改变了脂多糖(LPS) - 活化的巨噬细胞的蛋白质组,但不影响LPS驱动的细胞因子产生或达洛样受体4内吞作用

获取原文
获取外文期刊封面目录资料

摘要

Siglec-E is a murine CD33-related siglec that functions as an inhibitory receptor and is expressed mainly on neutrophils and macrophage populations. Recent studies have suggested that siglec-E is an important negative regulator of lipopolysaccharide (LPS)-toll-like receptor 4 (TLR4) signaling and one report ( 1 ) claimed that siglec-E is required for TLR4 endocytosis following uptake of Escherichia coli by macrophages and dendritic cells (DCs). Our attempts to reproduce these observations using cells from wild-type (WT) and siglec-E-deficient mice were unsuccessful. We used a variety of assays to determine if siglec-E expressed by different macrophage populations can regulate TLR4 signaling in response to LPS, but found no consistent differences in cytokine secretion in vitro and in vivo , comparing three different strains of siglec-E-deficient mice with matched WT controls. No evidence was found that the siglec-E deficiency was compensated by expression of siglecs-F and -G, the other murine inhibitory CD33-related siglecs. Quantitative proteomics was used as an unbiased approach and provided additional evidence that siglec-E does not suppress inflammatory TLR4 signaling. Interestingly, proteomics revealed a siglec-E-dependent alteration in macrophage protein composition that could be relevant to functional responses in host defense. In support of this, siglec-E-deficient mice exhibited enhanced growth of Salmonella enterica serovar Typhimurium in the liver following intravenous infection, but macrophages lacking siglec-E did not show altered uptake or killing of bacteria in vitro . Using various cell types including bone marrow-derived DCs (BMDCs), splenic DCs, and macrophages from WT and siglec-E-deficient mice, we showed that siglec-E is not required for TLR4 endocytosis following E. coli uptake or LPS challenge. We failed to see expression of siglec-E by BMDC even after LPS-induced maturation, but confirmed previous studies that splenic DCs express low levels of siglec-E. Taken together, our findings do not support a major role of siglec-E in regulation of TLR4 signaling functions or TLR4 endocytosis in macrophages or DCs. Instead, they reveal that induction of siglec-E by LPS can modulate the phenotype of macrophages, the functional significance of which is currently unclear.
机译:Siglec-e是一种鼠CD33相关的Siglec,其用作抑制受体,主要表达在中性粒细胞和巨噬细胞群体上。最近的研究表明,SigleC-E是脂多糖(LPS) - 托尔样受体4(TLR4)信号传导的重要负调节剂,并且一份报告(1)要求SIGLEC-E需要在吸收大肠杆菌后的TLR4内吞作用巨噬细胞和树突细胞(DCS)。我们试图使用来自野生型(WT)和Siglec-E缺陷小鼠的细胞再现这些观察结果不成功。我们使用各种测定来确定由不同巨噬细胞群表达的SigleC-E可以调节TLR4信号传导响应于LPS,但发现在体外和体内细胞因子分泌中没有一致的差异,比较三种不同的Siglec-E缺陷株匹配的WT控制小鼠。发现没有证据表明Siglecs-F和-G的表达补偿了Siglecs-F和-G,其他小鼠抑制CD33相关的Siglecs补偿。用定量蛋白质组学用作无偏见的方法,并提供额外的证据,即SigleC-E不抑制炎症TLR4信号传导。有趣的是,蛋白质组学揭示了巨噬细胞蛋白质组合物的Siglec-E依赖性改变,其可能与主体防御中的功能反应相关。为了支持这一点,Siglec-E缺陷小鼠表现出静脉感染后肝脏在肝脏中的Salmonella肠道毒蕈Typhimurium的增强,但缺乏Siglec-E的巨噬细胞没有显示出改变的摄取或体外杀死细菌的杀伤。使用包括骨髓衍生的DC(BMDCS),脾脏DC和来自WT和Siglec-E缺乏小鼠的巨噬细胞的各种细胞类型,我们表明,在大肠杆菌摄取或LPS挑战之后,TLR4内吞作用不需要SigleC-E。即使在LPS诱导的成熟后,我们也未能通过BMDC表达SigleC-E的表达,但是先前的研究表明脾脏直流表达低水平的SIGLEC-E。在一起,我们的研究结果不支持SigleC-E在巨噬细胞或DCS中调节TLR4信号传导功能或TLR4内吞作用的主要作用。相反,它们揭示了LPS的诱导酶可以调节巨噬细胞的表型,其功能意义目前不清楚。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号